A New Front: India’s Natco Gets State-level Nod To Sell Copies Of BMS’ Sprycel
This article was originally published in PharmAsia News
Natco has gained approval from a state-level agency rather than India’s DCGI, opening up a new front in the battle between Indian companies and MNCs.
You may also be interested in...
On BMS’ Plea, Delhi Court Nixes Hetero’s Dasatinib Application; Directs India’s Drug Controller To Examine Patent Violations
MUMBAI - In a decision that could have a far-reaching impact on drug patent cases in India, the Delhi High Court has directed the Drug Controller General of India to monitor for patent infringements by any party while a drug's approval application is scrutinized
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.